Tisotumab vedotin-tftv (Tivdak), an antibody-drug conjugate, has been granted accelerated approval for the treatment of recurrent or metastatic cervical cancer.
FDA Approvals
Tisotumab vedotin-tftv (Tivdak), an antibody-drug conjugate, has been granted accelerated approval for the treatment of recurrent or metastatic cervical cancer.
FDA Approvals
